Anna H. Chen is a Vice President at Frazier Life Sciences, a life sciences venture firm investing globally in private and publicly traded therapeutics companies. She focuses on evaluating new investment opportunities and creating new ventures. Anna has been involved in Frazier’s creation of and investments in Amunix (acquired by Sanofi), Lengo (acquired by Blueprint), Hillevax (NASDAQ: HLVX), SanReno, and others. Prior to joining Frazier, Anna was a management consultant at L.E.K. consulting, advising leading biopharma clients on strategic planning, M&A, R&D and BD strategy. She received her Ph.D. in systems biology and A.B. in biochemical sciences from Harvard University.